Navigation Links
Peripheral Arterial Disease (PAD) - Pipeline Assessment and Market Forecasts to 2017 Now Available at ReportsandReports
Date:11/1/2010

ctor contributing to the increase in growth over the forecast period is the increase in disease incidence and the launch of new first-in-class drugs. Presently the therapeutic regimen for PAD consists of antiplatelet agents such as clopidogrel (Plavix) and ticlopidine (Ticlid). Blood thinners such as pentoxifyline (Trental) and Cilostazol (Pletal) are also prescribed. Like most cardiovascular complications, aspirin is used as a complementary drug in combination with the above mentioned drugs.

Scope

The report provides information on the key drivers and challenges of the PAD market. Its scope includes: - Annualized global PAD market revenues data from 2001 to 2009, forecast for eight years to 2017. - Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as of gene therapy, stem cell therapy, platelet aggregation inhibitor, Hydroxymethylglutaryl-CoA reductase inhibitor, monoclonal antibody, micro RNA, protein kinase modulator, Y2 agonist, and PPAR (Peroxisome Proliferator Activated Receptor) agonist. - Analysis of the current and future competition in the global PAD market. Key market players covered are Sanofi Aventis, Indigo pharmaceuticals, BioMarin Pharmaceutical, and AnGes MG Inc. - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. - Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the PAD therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to: - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. - Develop business strateg
'/>"/>

SOURCE MarketsandMarkets
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Peripheral Artery Disease (PAD) Patent Granted to Dimera
2. CeNeRx BioPharma Awarded New Patent for its Innovative Compounds That Selectively Target Peripheral Cannabinoid Receptors
3. Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant
4. ev3 Inc. Receives FDA Clearance to Market EverCross and NanoCross Peripheral Angioplasty Balloons
5. Actelion Launches Increased Strength Formulation of Ventavis (Iloprost) for Pulmonary Arterial Hypertension in the United States
6. Pulmonary Hypertension Association Names Dr. Nicholas Hill Recipient of 2009 Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care
7. Distinguished Scientist H. Mario Geysen Joins SRI International to Lead Combinatorial Sciences and Metabolic Diseases Research Programs
8. Davis Phinney Foundation Launches Exercise-Focused Tools to Help People Live Well With Parkinsons Disease
9. HumanTouch Expands Services to the Centers for Disease Control and Prevention as a Prime Contract Holder as Part of $1.0 Billion Contract
10. 550 People Across Europe Will Die Today From a Preventable Lung Disease
11. NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of a New Dermal Patch for Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2014)... NY (PRWEB) July 26, 2014 ... provides key market data on the Canada Endoscopy ... millions of US dollars, volume (in units) and ... - High-End Endoscopy Visualization Systems, Mid-Range Endoscopy Visualization ... Full Report at http://www.marketresearchreports.biz/analysis/213254 . , The ...
(Date:7/25/2014)... 26, 2014 "Ischemic Stroke and ... provides data on the Ischemic Stroke and Cerebral ... information and data relating to the clinical trials ... full global Ischemic Stroke Research Report 2014 at: ... of the trial numbers and their recruitment status ...
(Date:7/25/2014)... , July 25, 2014 Amgen (NASDAQ: ... today declared a $0.61 per share dividend for the ... on Sept. 5, 2014, to all stockholders of record ... 2014.  About Amgen Amgen is committed ... from serious illnesses by discovering, developing, manufacturing and delivering ...
(Date:7/25/2014)... bacteria live in each person,s digestive tract. Scientists believe ... stave off harmful infections, but their role in human ... light on the role of these bacteria, a team ... recently tracked fluctuations in the bacterial populations of two ... in the July 25 issue of the journal ...
Breaking Biology Technology:Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3
... BioMarin Pharmaceutical,Inc. (Nasdaq: BMRN ) today announced that ... update at the Piper,Jaffray Healthcare Conference in New York City ... Interested parties may access a ... of the BioMarin website, http://www.BMRN.com . A,replay of the ...
... Germany, November 25 t2cure, a,biopharmaceutical company developing ... today announced that it has acquired a family ... transfer arm,of Frankfurt University. , ... that allows for the rapid characterization,of the potency ...
... Genoptix, Inc. (Nasdaq: GXDX ), a specialized laboratory services ... Jaffray Healthcare Conference scheduled to take place at the New York ... , , Dr. Tina S. ... on Wednesday, December 3, beginning at approximately 2:00 p.m. EST. ...
Cached Biology Technology:BioMarin to Present at the Piper Jaffray Healthcare Conference 2t2cure Acquires Patent Family on In Vitro Potency Testing of Stem Cells for Cardiovascular Application 2Genoptix Announces Participation at the Twentieth Annual Piper Jaffray Healthcare Conference 2
(Date:7/24/2014)... The University of Texas Health Science Center at Houston ... help Harris County residents whose vision problems cannot be ... corrective lenses, many people with low vision can see ... low vision devices, such as telescopes, magnifiers and electronic ... is using the three-year, $164,645 SightFirst grant from the ...
(Date:7/24/2014)... week for an all-day public forum on a $1.7 ... to dredge toxic sediment from an eight-mile stretch of ... the plan, which proposes removing 4.3 million cubic yards ... one of the largest cleanups in the agency,s history. ... , "We need to ensure the future well-being of ...
(Date:7/24/2014)... hazard in the United States, wildland managers often utilize ... suppressed trees (ladder fuels). These cuttings and other ... fire danger in order to dispose of the material. ... managers often cover all or part of the debris ... agricultural plastic, in order to keep water out. A ...
Breaking Biology News(10 mins):UTHealth Dr. Bhavani Iyer awarded low vision grant 2Experts Weigh the Pros and Cons of a $1.7 Billion EPA Cleanup Plan for the Passaic River at an NJIT 2Study gives new perspective on agricultural plastic, debris burning, and air quality 2
... hold great promise for benefiting degenerative diseases, and do ... grown in a manner compatible with clinical use (i.e., ... for immunosuppression. These were a few of a number ... by Evan Y. Snyder, M.D., Ph.D., and spearheaded by ...
... from another may depend on the number of receptors ... of receptors is controlled by levels of a ubiquitous ... found. , Everything from the ability to concentrate, perceive ... sclerosis, muscular dystrophy, post-traumatic stress syndrome and schizophrenia is ...
... launch of the first large-scale study to evaluate a ... today by study collaborators in the United States and ... participants at five sites throughout South Africa and is ... are part of the HIV Vaccine Trials Network (HVTN), ...
Cached Biology News:Stem cells act through multiple mechanisms to benefit mice with neurodegenerative disease 2Stem cells act through multiple mechanisms to benefit mice with neurodegenerative disease 3Stem cells act through multiple mechanisms to benefit mice with neurodegenerative disease 4Stem cells act through multiple mechanisms to benefit mice with neurodegenerative disease 5Bisexual fruit flies show new role for neurochemical 2Africa's first large-scale HIV vaccine study launches 2Africa's first large-scale HIV vaccine study launches 3Africa's first large-scale HIV vaccine study launches 4
MAb to Yersinia pestis F1 Ag. Yersinia pestis F1 Antigen EB Strain...
Mouse monoclonal antibody to QDPR - quinoid dihydropteridine reductase...
... Chromogen System consists of FAST RED chromogen,tablets ... the presence of alkaline phosphatase to produce ... The FAST RED System provides enough material ... , , Vial A: 6 Tablets , ...
The BioLogic Maximizer mixer is for use with the Maximizer valve system. The mixer improves gradient quality by mixing the output of the BioLogic DuoFlow workstation pumps....
Biology Products: